2024
The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy
Ahluwalia M, Liu J, Olivotto I, Parikh V, Ashley E, Michels M, Ingles J, Lampert R, Stendahl J, Colan S, Abrams D, Pereira A, Rossano J, Ryan T, Owens A, Ware J, Saberi S, Helms A, Day S, Claggett B, Ho C, Lakdawala N. The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Heart Failure 2024 PMID: 39520446, DOI: 10.1016/j.jchf.2024.09.008.Peer-Reviewed Original ResearchObstructive hypertrophic cardiomyopathyClass I patientsFunctional class II patientsNYHA functional class IClass II patientsFunctional class II patientsII patientsHypertrophic cardiomyopathyFollow-upLeft ventricular outflow tract obstructionVentricular outflow tract obstructionNYHA functional class IILeft ventricular ejection fractionRates of clinical outcomesClass INatural historyRestricted cubic spline modelsSeptal reduction therapyOutflow tract obstructionFunctional class IIVentricular ejection fractionComposite event rateCubic spline modelsCox proportional hazardsLong-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry
Maurizi N, Antiochos P, Owens A, Lakdwala N, Saberi S, Russell M, Fumagalli C, Skalidis I, Lin K, Nathan A, De Feria Alsina A, Reza N, Stendahl J, Abrams D, Semsarian C, Clagget B, Lampert R, Wheeler M, Parikh V, Ashley E, Michels M, Rossano J, Ryan T, Ingles J, Ware J, Ho C, Helms A, Day S, Olivotto I. Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry. Circulation 2024, 150: 1377-1390. PMID: 39355918, PMCID: PMC11493522, DOI: 10.1161/circulationaha.124.069378.Peer-Reviewed Original ResearchSeptal reduction therapyHCM-related deathOutflow tract obstructionObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyHeart failureComposite outcomeMaximal left ventricular outflow tract gradientRecurrent left ventricular outflow tract obstructionRelief of outflow tract obstructionLeft ventricular outflow tract gradientLeft ventricular outflow tract obstructionReduction therapyVentricular outflow tract obstructionDe novo atrial fibrillationPredictor of adverse outcomesOccurrence of heart failureAlcohol septal ablationOutflow tract gradientEvent-free survivalLong-term disease courseHypertrophic cardiomyopathy centersLong-term reliefCox proportional hazards modelsLong-term outcomesLong‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Shah A, Fox S, Wang A. Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study. Journal Of The American Heart Association 2024, 13: e030607. PMID: 38591260, PMCID: PMC11262496, DOI: 10.1161/jaha.123.030607.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire–Overall Summary scoreSymptomatic obstructive hypertrophic cardiomyopathyOutflow tract gradientHypertrophic cardiomyopathyNew York Heart Association class improvementLeft ventricular outflow tract gradientTreatment-emergent adverse eventsSerum NT-proBNP levelsLeft ventricular ejection fractionEffect of mavacamtenIndividual dose titrationNT-proBNP levelsVentricular ejection fractionSerum NT-proBNPSummary scoreLong-term safetyLonger-term treatmentDose titrationEjection fractionNT-proBNPB-blockersReduced doseAdverse eventsInterim resultsPREDICTORS OF ADVERSE LONG-TERM OUTCOME AFTER SEPTAL REDUCTION THERAPIES IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY : INSIGHTS FROM THE SHARE REGISTRY
Maurizi N, Antiochos P, Owens A, Lakdawala N, Saberi S, Russell M, Lin K, De Feria Alsina A, Reza N, Stendahl J, Abrams D, Semsarian C, Lampert R, Parikh V, Wheeler M, Ashley E, Michels M, Rossano J, Ryan T, Ingles J, Ware J, Ho C, Helms A, Day S, Olivotto I. PREDICTORS OF ADVERSE LONG-TERM OUTCOME AFTER SEPTAL REDUCTION THERAPIES IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY : INSIGHTS FROM THE SHARE REGISTRY. Journal Of The American College Of Cardiology 2024, 83: 353. DOI: 10.1016/s0735-1097(24)02343-x.Peer-Reviewed Original ResearchPredictor of adverse long-term outcomesObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathy
2023
LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Fox S, Wang A. LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY. Journal Of The American College Of Cardiology 2023, 81: 346. DOI: 10.1016/s0735-1097(23)00790-8.Peer-Reviewed Original ResearchHypertrophic cardiomyopathySymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyPatients